UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING	G DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/726,878	12/0	2/2003	Charles Price Taylor JR.	PC26098A	5420
²⁸⁵²³ PFIZER INC	7590	10/17/2007		EXAMINER	
PATENT DE	PARTMENT	HENLEY III, RAYMOND J			
GROTON, C	DINT ROAD Γ 06340			ART UNIT	PAPER NUMBER
, , , , ,				1614	
		•		MAIL DATE	DELIVERY MODE
				10/17/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)					
	10/726,878	TAYLOR ET AL.					
Office Action Summary	Examiner	Art Unit					
	Raymond J. Henley III	1614					
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 16(a). In no event, however, may a reply be tim rill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONEI	L. viely filed the mailing date of this communication. D (35 U.S.C. § 133).					
Status	•						
Responsive to communication(s) filed on <u>28 Not</u> This action is FINAL . 2b)⊠ This Since this application is in condition for allowant closed in accordance with the practice under E	action is non-final. ace except for formal matters, pro						
Disposition of Claims							
4) ⊠ Claim(s) 2-9 and 11-16 is/are pending in the ap 4a) Of the above claim(s) 9,11,12 and 16 is/are 5) ⊠ Claim(s) 2, 5-8 and 13-15 is/are allowed. 6) ⊠ Claim(s) 3 and 4 is/are rejected. 7) ⊠ Claim(s) 9 and 16 is/are objected to. 8) □ Claim(s) are subject to restriction and/or	withdrawn from consideration.						
Application Papers							
9) The specification is objected to by the Examiner 10) The drawing(s) filed on is/are: a) access applicant may not request that any objection to the conference of the	epted or b) objected to by the Edrawing(s) be held in abeyance. See on is required if the drawing(s) is obj	e 37 CFR 1.85(a). ected to. See 37 CFR 1.121(d).					
Priority under 35 U.S.C. § 119							
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.							
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	te					

Art Unit: 1614

CLAIMS 2-9 AND 11-16 ARE PRESENTED FOR EXAMINATION

Applicants' amendment filed November 28, 2006 has been received and entered.

Accordingly, the claims have been amended as indicated.

Applicants' remarks and/or amendments have overcome the issues raised in the previous Office action dated August 30, 2006 which are not reiterated herein therefrom. Accordingly, such issues are here *withdrawn*.

That which is set forth, *infra*, constitutes the totality of issues remaining in the present application.

Claim Objection

Claims 9 and 16 are objected to under 37 CFR 1.75(c) as being in improper form because a multiple dependent claim must refer to other claims in the alternative only. See MPEP § 608.01(n). Accordingly, the claims have not been further treated on the merits.

In order to over come this objection, "claimed in claims 3-8", (claim 9), should be amended to read "anyone of claims 3-9".

Election/Restriction

As per the requirement for restriction set forth in the Office action dated March 24, 2006, as well as Applicants' response thereto entered June 8, 2006, claims 11-12 remain withdrawn from consideration under 37 C.F.R. § 1.142(b).

Claims 2-8 and 13-15 are herein acted on the merits. The scope of the Examiner's consideration has been extended to the species represented in newly amended claims 3-5.

Art Unit: 1614

Claim Rejection - 35 USC § 112, Second Paragraph

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 3 and 4 rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

"The primary purpose of this requirement of definiteness of claim language is to ensure that the scope of the claims is clear so the public is informed of the boundaries of what constitutes infringement of the patent. A secondary purpose is to provide a clear measure of what applicants regard as the invention so that it can be determined whether the claimed invention meets all the criteria for patentability and whether the specification meets the criteria of 35 U.S.C. 112, first paragraph with respect to the claimed invention.", (see MPEP § 2173).

The term "derivative" appearing in the expression "a pharmaceutically acceptable derivative", is a relative term which renders the claim indefinite. In particular, "derivative" does not particularly point out the degree or type of derivation that a given compound may have in relation to the parent compound and still be considered a "derivative" as intended by Applicants.

Applicants have failed to provide any specific definition for this term in the present specification. Lacking such a definition, the skilled artisan would not be reasonably apprised of the metes and bounds of the subject matter for which Applicants seek patent protection. Rather, a subjective interpretation of the claimed language would be required. However, as such is deemed inconsistent with the tenor and express language of 35 U.S.C. § 112, second paragraph, the claims are deemed properly rejected.

Art Unit: 1614

Allowable Subject Matter

Claims 2, 5-8 and 13-15 appear in condition for allowance as the prior art fails to teach or suggest the presently claimed methods for treating premature ejaculation.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Raymond J. Henley III whose telephone number is 571-272-0575. The examiner can normally be reached on M-F, 8:30 am to 4:00 pm Eastern Time.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ardin H. Marschel can be reached on 571-272-0718. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Primary Examine

Art Unit 1614